Toronto - Delayed Quote CAD

Knight Therapeutics Inc. (GUD.TO)

6.09

+0.09

+(1.50%)

At close: June 12 at 4:00:00 PM EDT

Knight Therapeutics and Sumitomo Pharma enter into Exclusive Licensing Agreements to commercialize Sumitomo’s Canadian Portfolio

MONTREAL and MARLBOROUGH, Mass., June 05, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, and Sumitomo Pharma America Inc. (“SMPA”) announced today that Knight and SMPA’s affiliates have entered into exclusive license and supply agreements to commercialize MYFEMBREE® (relugolix/estradiol/norethindrone acetate), ORGOVYX® (relugolix) and vibegron in Canada, as well as an asset purchase agreement under which Knight w

GlobeNewswire 7 days ago

KHTRF
TSX Growth Companies With Insider Ownership Up To 22%

In the current Canadian market landscape, investors are keeping a close watch on potential changes to U.S. tax policies that could impact dividends received from American companies, alongside rising bond yields signaling shifts in global fiscal dynamics. Amid these developments, growth companies with high insider ownership can offer a compelling investment narrative, as insider confidence often aligns with strong business fundamentals and long-term potential.

Simply Wall St. 16 days ago

WHTCF

AAUCD

KHTRF
Knight Therapeutics First Quarter 2025 Earnings: EPS Beats Expectations

Knight Therapeutics ( TSE:GUD ) First Quarter 2025 Results Key Financial Results Revenue: CA$88.1m (up 1.7% from 1Q...

Simply Wall St. 29 days ago

KHTRF
Knight to Present at the 2025 RBC Capital Markets Global Healthcare Conference in New York City

MONTREAL, May 13, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-US) specialty pharmaceutical company, announced today that Samira Sakhia, President and Chief Executive Officer, is scheduled to participate in a fireside chat at the 2025 RBC Capital Markets Global Healthcare Conference on Tuesday, May 20, 2025 at 3:35 pm ET at the InterContinental New York Barclay hotel in New York City. About Knight Therapeutics Inc. Knight Therapeutics Inc., headquar

GlobeNewswire 30 days ago

KHTRF
Knight Therapeutics Reports First Quarter 2025 Results

MONTREAL, May 08, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight" or “the Company”), a pan-American (ex-US) specialty pharmaceutical company, today reported financial results for its first quarter ended March 31, 2025. All currency amounts are in thousands except for share and per share amounts. All currencies are Canadian unless otherwise specified. Q1-25 Highlights Financial results Revenues were $88,076, an increase of $1,472 or 2% over the same period in prior year. Th

GlobeNewswire last month

KHTRF
Knight Therapeutics Inc. announces voting results from the Annual General Meeting

MONTREAL, May 07, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX:GUD) ("Knight" or the "Corporation") a pan-American (ex-US) specialty pharmaceutical company, announced today the voting results from the Annual General Meeting of the Shareholders held virtually in Montreal, Quebec ("Meeting"). Election of Directors Each director nominee listed in the Management Information Circular dated April 4, 2025 ("Circular") was elected as Director of the Corporation at the Meeting. Shareholders pre

GlobeNewswire last month

KHTRF
Knight Therapeutics Announces Relaunch of ONICIT® in Brazil and Mexico

MONTREAL, May 07, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that has assumed full commercial activities and is relaunching ONICIT® IV (palonosetron) in Brazil and Mexico, through its affiliates in those countries (United Medical Ltd. and Grupo Biotoscana de Especialidad S.A. de C.V., respectively). In May 2022, Knight and Helsinn Healthcare SA ("Helsinn") had entered into an exclusive license

GlobeNewswire last month

KHTRF
Notice of Knight Therapeutics' First Quarter 2025 Results Conference Call

MONTREAL, May 01, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a pan-American (ex-USA) specialty pharmaceutical company, will release its first quarter 2025 financial results on Thursday, May 8, 2025 prior to market opening. Following the release, Knight will hold a conference call and audio webcast. Knight cordially invites all interested parties to participate in this call. Date: Thursday, May 8, 2025 Time: 8:30 a.m. ET Telephone: Toll Free: 1-888-699-1199 or Intern

GlobeNewswire last month

KHTRF
Knight to Present at the 2025 Bloom Burton & Co. Healthcare Investor Conference

MONTREAL, April 29, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a pan-American (ex-US) specialty pharmaceutical company, announced today that Samira Sakhia, President and Chief Executive Officer, is scheduled to present a corporate update at the Bloom Burton & Co. Healthcare Investor Conference on Monday, May 5, 2025, at 2:00 p.m. ET at the Metro Toronto Convention Centre (North Building) in Toronto. A copy of the presentation will be available at www.knighttx.com. A

GlobeNewswire last month

KHTRF
TSX Growth Companies With High Insider Ownership April 2025

As the Canadian market navigates a period of cautious optimism, with the TSX only slightly off its record high thanks to strong performance in sectors like materials, investors are keenly observing how trade developments and pro-growth agendas will shape future trends. In this environment, identifying growth companies with high insider ownership can be particularly appealing, as such stocks often signal confidence from those closest to the business and may offer resilience amid market...

Simply Wall St. last month

AAUCF

WHTCF

KHTRF
Knight Therapeutics Inc. ranks on The Globe and Mail’s sixth-annual Women Lead Here benchmark of executive gender diversity

MONTREAL, March 28, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight” or “the Company”) is pleased to announce it will be recognized on The Globe and Mail’s 2025 Report on Business magazine’s sixth annual Women Lead Here list. This annual editorial benchmark identifies top-level Canadian businesses with the highest executive gender diversity. “We are both proud and humble to have Knight Therapeutics Inc. once again featured on the Globe and Mail’s Report on Canada’s Women Le

GlobeNewswire 2 months ago

KHTRF
TSX Growth Stocks With Up To 86% Insider Driven Earnings Expansion

As the Federal Reserve maintains its interest rates and economic growth shows signs of cooling, Canadian markets are navigating a landscape marked by rising inflation and potential rate cuts from the Bank of Canada. In this environment, stocks with high insider ownership can be appealing as they often signal strong confidence from those closest to the company, potentially aligning well with investor interests in times of economic uncertainty.

Simply Wall St. 2 months ago

AOIFF

KHTRF

AAUCF
Knight Therapeutics Full Year 2024 Earnings: Beats Expectations

Knight Therapeutics ( TSE:GUD ) Full Year 2024 Results Key Financial Results Revenue: CA$371.3m (up 13% from FY 2023...

Simply Wall St. 2 months ago

KHTRF
Knight Therapeutics Announces Launch of Minjuvi® (tafasitamab) in Mexico

MONTREAL, March 26, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight"), a pan-American (ex-US) specialty pharmaceutical company, announced today the launch of Minjuvi® (tafasitamab) by its Mexican affiliate, Grupo Biotoscana de Especialidad S.A. de C.V. Minjuvi® in combination with lenalidomide, followed by Minjuvi® monotherapy, is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), who are not eligible for autolo

GlobeNewswire 2 months ago

KHTRF

INCY
Knight Therapeutics Inc (KHTRF) Q4 2024 Earnings Call Highlights: Record Revenue Growth Amidst ...

Knight Therapeutics Inc (KHTRF) reports a 6% revenue increase to over $365 million, while facing a 4% decline in adjusted EBITDA for 2024.

GuruFocus.com 2 months ago

KHTRF
Knight Therapeutics Reports Fourth Quarter and Year-End 2024 Results

Reports record-high revenues since inceptionMONTREAL, March 20, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight" or “the Company”), a pan-American (ex-US) specialty pharmaceutical company, today reported financial results for its fourth quarter and year ended December 31, 2024. All currency amounts are in thousands except for share and per share amounts. All currencies are Canadian unless otherwise specified. 2024 Highlights Financial results Revenues were $371,304, an incr

GlobeNewswire 2 months ago

KHTRF
Notice of Knight Therapeutics' Fourth Quarter and Year End 2024 Results Conference Call

MONTREAL, March 13, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a pan-American (ex-USA) specialty pharmaceutical company, will release its fourth quarter and year end 2024 financial results on Thursday, March 20, 2025 prior to market opening. Following the release, Knight will hold a conference call and audio webcast. Knight cordially invites all interested parties to participate in this call. Date: Thursday, March 20, 2025Time: 8:30 a.m. ETTelephone: Toll Free: 1-88

GlobeNewswire 2 months ago

KHTRF
Knight Therapeutics Price Target Raised at RBC, Raymond James

Analysts at RBC Capital Markets and Raymond James raised their price targets on Knight Therapeutics

PREMIUM
MT Newswires 2 months ago

KHTRF
Knight Therapeutics to Acquire Paladin

MONTREAL, March 11, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a pan-American (ex-US) specialty pharmaceutical company, announced today that it has entered into a definitive Asset Purchase Agreement (“APA”) with Endo Operations Limited (“Endo”) and Paladin Pharma Inc., to acquire the Paladin business (“Paladin”). At closing, Knight will pay an upfront payment of $120 million in cash, including inventory with a value of $20 million. In addition, Knight may pay future

GlobeNewswire 3 months ago

KHTRF
TSX Growth Companies With High Insider Ownership In February 2025

As we enter February 2025, the Canadian market has seen a modest 3% rise, navigating through stabilized yields and contained inflation rates. In this environment, growth companies with high insider ownership can be particularly appealing as they often indicate strong confidence from those closest to the business, providing a potential buffer against economic uncertainties.

Simply Wall St. 3 months ago

BDRAF

BDRBF

BDRPF

Performance Overview

Return	GUD.TO	S&P/TSX Composite index (^GSPTSE)
YTD	+16.00%	+8.10%
1-Year	+3.92%	+21.19%
3-Year	+16.00%	+31.28%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Knight Therapeutics Inc. (GUD.TO)

Knight Therapeutics and Sumitomo Pharma enter into Exclusive Licensing Agreements to commercialize Sumitomo’s Canadian Portfolio

TSX Growth Companies With Insider Ownership Up To 22%

Knight Therapeutics First Quarter 2025 Earnings: EPS Beats Expectations

Knight to Present at the 2025 RBC Capital Markets Global Healthcare Conference in New York City

Knight Therapeutics Reports First Quarter 2025 Results

Knight Therapeutics Inc. announces voting results from the Annual General Meeting

Knight Therapeutics Announces Relaunch of ONICIT® in Brazil and Mexico

Notice of Knight Therapeutics' First Quarter 2025 Results Conference Call

Knight to Present at the 2025 Bloom Burton & Co. Healthcare Investor Conference

TSX Growth Companies With High Insider Ownership April 2025

Knight Therapeutics Inc. ranks on The Globe and Mail’s sixth-annual Women Lead Here benchmark of executive gender diversity

TSX Growth Stocks With Up To 86% Insider Driven Earnings Expansion

Knight Therapeutics Full Year 2024 Earnings: Beats Expectations

Knight Therapeutics Announces Launch of Minjuvi® (tafasitamab) in Mexico

Knight Therapeutics Inc (KHTRF) Q4 2024 Earnings Call Highlights: Record Revenue Growth Amidst ...

Knight Therapeutics Reports Fourth Quarter and Year-End 2024 Results

Notice of Knight Therapeutics' Fourth Quarter and Year End 2024 Results Conference Call

Knight Therapeutics Price Target Raised at RBC, Raymond James

Knight Therapeutics to Acquire Paladin

TSX Growth Companies With High Insider Ownership In February 2025

Performance Overview